Utilizing transgenic mice overexpressing FIBCD1 in the intestinal tissues, thereby mimicking its expression in the human gut, we found that expression of FIBCD1 significantly alleviated intestinal inflammation, increased survival, and decreased tumor formation as well as burden in a mouse model of inflammation-driven colorectal cancer. Here, FIBCD1 is linked to colorectal cancer.